Key Finding: A new paper in Cells reviews evidence that declining estrogen levels after menopause alter epigenetics—the system controlling gene activation—potentially explaining increased risks of heart disease, diabetes, and other metabolic conditions.
Heart disease is the leading cause of death for women, and risk increases during and after menopause, according to the National Heart, Lung, and Blood Institute.
The Estrogen-Epigenetics Link
The study, led by Sumita Mishra at Virginia Tech's Fralin Biomedical Research Institute, examines how estrogen loss may change gene regulation without altering DNA. These epigenetic changes may affect cardiovascular health, linking hormone loss to long-term regulatory shifts.
Interventions That May Intersect
The research notes that interventions such as lipid-lowering therapies, GLP-1 receptor agonists, SGLT2 inhibitors, diet, and exercise may intersect with estrogen-influenced gene regulatory pathways.
Current Evidence
Most mechanistic evidence comes from laboratory and preclinical studies; more human research is needed to confirm these findings.
Related Work
Mishra's laboratory also studies heart failure with preserved ejection fraction (HFpEF), a condition affecting women disproportionately after menopause. Related findings were published in Hypertension.